Published in Gene Therapy Weekly, August 26th, 2004
This is the first sub-study to evaluate patients more than 8 years after they completed adjuvant treatment with epirubicin hydrochloride injection (brand name: Ellence; Pharmacia Corp. [now Pfizer]) and builds upon results of the FASG-05 study, which demonstrated significant 5- and 10-year disease-free and overall survival benefits in patients treated with Ellence, an anthracycline cytotoxic agent.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.